Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Pharmacokinetics of Landiolol and Its Metabolite M1 During Renal Replacement Therapy in Septic Shock Patients: A Sub-Study of the Landi-SEP Trial.European journal of drug metabolism and pharmacokinetics · 2026
   Trial
2. Soft drugs: design principles and topical applications.Nature reviews. Drug discovery · 2026
   Review
3. Landiolol in perioperative and critical care: evidence, patient selection, and practical titration for targeted heart rate control: a narrative review.Journal of anesthesia, analgesia and critical care · 2026
   Review
4. Targeted Heart Rate Control with Landiolol in Hemodynamically Unstable, Non-Surgical Intensive Care Unit Patients: A Comparative Study.Medicina (Kaunas, Lithuania) · 2025
   Article
5. Hemodynamic Changes Following Landiolol Initiation in Patients With Critical Illness Who Developed Tachycardia During Dobutamine Infusion: A Retrospective Observational Study.Cureus · 2025
   Article
6. Comparison of the efficacy and safety of Landiolol and Esmolol in critically ill patients: a propensity score-matched study.Annals of intensive care · 2025
   Article
7. Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia.Medicina (Kaunas, Lithuania) · 2024
   Article
8. Mechanisms of landiolol-mediated positive inotropy in critical care settings.European journal of clinical pharmacology · 2023
   Review
9. Hemodynamic and Rhythmologic Effects of Push-Dose Landiolol in Critical Care-A Retrospective Cross-Sectional Study.Pharmaceuticals (Basel, Switzerland) · 2023
   Article
10. Benefits and safety of landiolol for rapid rate control in patients with atrial tachyarrhythmias and acute decompensated heart failure.European heart journal supplements : journal of the European Society of Cardiology · 2022
    Article
11. Acute rate control in atrial fibrillation: an urgent need for the clinician.European heart journal supplements : journal of the European Society of Cardiology · 2022
    Article
12. [Heart rate control in shock].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2022
    Review
13. Expert consensus on acute management of ventricular arrhythmias - VT network Austria.International journal of cardiology. Heart & vasculature · 2021
    Review
14. Effects of Intravenous Landiolol on Heart Rate and Outcomes in Patients with Atrial Tachyarrhythmias and Acute Decompensated Heart Failure: A Single-Center Experience.Drugs - real world outcomes · 2019
    Article
15. Landiolol for managing atrial fibrillation in post-cardiac surgery.European heart journal supplements : journal of the European Society of Cardiology · 2018
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as